News from daiichi sankyo, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 02, 2016, 08:30 ET

Daiichi Sankyo to Expand Access to Clinical Trial Data

Daiichi Sankyo Co., Ltd. (head office: Chuo-ku, Tokyo; Representative Director, President and CEO: Joji Nakayama) (hereinafter "Daiichi Sankyo"),...

Nov 10, 2015, 16:11 ET

Daiichi Sankyo and Plexxikon Announce FDA Approval of Cobimetinib in Combination with Zelboraf® (vemurafenib) in Advanced Melanoma

 Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced the U.S. Food and Drug Administration (FDA)...

Nov 02, 2015, 08:01 ET

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA®/LIXIANA® in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015

Daiichi Sankyo, Inc. today announced that data from four new subgroup analyses from the phase 3 ENGAGE AF-TIMI 48 study will be presented at the...

Oct 30, 2015, 11:23 ET

FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor

 Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration...

Oct 16, 2015, 11:11 ET

Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline

Daiichi Sankyo, Inc. ("the Company") announced today that it will reorganize its U.S. Commercial organization as it begins to transition from a...

Oct 13, 2015, 03:00 ET
Click on the infographic above to learn more about atrial fibrillation and venous thromboembolism (PRNewsFoto/Daiichi Sankyo Company, Limited)

Daiichi Sankyo Partners With World Thrombosis Day to Promote Awareness of Venous Thromboembolism and Atrial Fibrillation, Helping to Reduce Preventable Deaths

World Thrombosis Day Interactive Infographic  Daiichi Sankyo is proud to partner with World Thrombosis Day to promote vital...

Oct 06, 2015, 21:53 ET

Daiichi Sankyo élargit son programme collaboratif de découverte de médicaments TaNeDS en Europe

Daiichi Sankyo Company, Limited (Daiichi Sankyo) a annoncé le 1er octobre les détails des candidatures pour son programme...

Oct 06, 2015, 21:53 ET

Daiichi Sankyo baut sein kooperatives Arzneimittelforschungsprogramm TaNeDS in Europa weiter aus

Daiichi Sankyo Company, Limited (nachstehend Daiichi Sankyo genannt) kündigte am 1. Oktober die Einzelheiten für die Anträge seiner...

Oct 05, 2015, 22:33 ET

Daiichi Sankyo ďalej rozširuje spoluprácu v rámci programu podpory objavovania liekov TaNeDS Europe

Daiichi Sankyo Company, Limited (ďalej len Daiichi Sankyo) oznámila 1. októbra podrobnosti ohľadne podávania...

Oct 05, 2015, 05:24 ET

Daiichi Sankyo expande el programa de descubrimiento de fármacos colaborativo TaNeDS en Europa

Daiichi Sankyo Company, Limited (de aquí en adelante, Daiichi Sankyo) anunció el 1 de octubre detalles de la aplicación para su...

Oct 04, 2015, 23:40 ET

Firma Daiichi Sankyo rozwija program współpracy w opracowywaniu nowych leków TaNeDS w Europie

1 października firma Daiichi Sankyo Company, Limited (zwana także Daiichi Sankyo) ogłosiła szczegóły aplikacji do...

Oct 02, 2015, 03:56 ET

Daiichi Sankyo dále rozšiřuje v Evropě společný program na objevování léků TaNeDS

Společnost Daiichi Sankyo Company, Limited (dále jako Daiichi Sankyo) oznámila dne 1. října detaily aplikace své...

Jul 29, 2015, 17:00 ET

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine (NEJM)...

Jul 13, 2015, 04:09 ET

NICE recommends once-daily LIXIANA® ▼ (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

NICE Final Appraisal Determination recommends that edoxaban is a cost effective use of NHS resources   The National Institute for Health...

Jul 09, 2015, 19:01 ET

New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice"

  Launch comes as new patients' survey reveals a significant proportion still not receiving adequate treatment for atrial fibrillation, the...

Jun 18, 2015, 08:00 ET

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational study, which...

Apr 01, 2015, 08:00 ET

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

 Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company,...

Mar 19, 2015, 06:00 ET

Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US

 Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US, in line with...

Feb 09, 2015, 07:59 ET

SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that SAVAYSA™ (edoxaban), an oral, once-daily selective factor...

Feb 04, 2015, 08:00 ET

Daiichi Sankyo Announces First Patients in Large-Scale, Multi-National Phase 3 Clinical Programs for Mirogabalin

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced enrollment of the first patients in large-scale, multi-national...